SanBio Co (TSE:4592) Treasury Stock : 円-1.08 Mil (As of Jul. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. SanBio Co's treasury stock for the quarter that ended in Jul. 2024 was 円-1.08 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

SanBio Co Treasury Stock Historical Data

The historical data trend for SanBio Co's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Treasury Stock Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Treasury Stock

Get a 7-Day Free Trial

-0.85

-0.90

-0.93

SanBio Co Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Treasury Stock	Get a 7-Day Free Trial															-0.90	-0.90	-0.93	-0.97	-1.08

SanBio Co Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

SanBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co Headlines

No Headlines